Almotriptan malate是5-HT1B/1D受体激动剂,可作用于偏头疼。
Almotriptan Malate is a selective 5-hydroxytryptamine1B/1D (5-HT1B/1D) receptor agonist, used for the treatment of Migraine attacks in adults.
动物 A (mg/kg) = 动物 B (mg/kg)×动物 B的Km系数/动物 A的Km系数 | |
例如,已知某工具药用于小鼠的剂量为88 mg/kg , 则用于大鼠的剂量换算方法:将88 mg/kg 乘以小鼠的Km系数(3),再除以大鼠的Km系数(6),得到该药物用于大鼠的等效剂量44 mg/kg。
[1] Joseph C Fleishaker,et al. Effect of MAO-A inhibition on the pharmacokinetics of almotriptan, an antimigraine agent in humans. Br J Clin Pharmacol. 2001 May; 51(5): 437–441. doi: 10.1046/j.1365-2125.2001.01367.x.
分子式 C17H25N3O2S.C4H6O5 |
分子量 469.56 |
CAS号 181183-52-8 |
储存方式 ﹣20 ℃冷藏长期储存。冰袋运输 |
溶剂(常温) |
DMSO 95 mg/mL |
Water <1 mg/mL |
Ethanol 55 mg/mL |
体内溶解度
NCT Number | Conditions | Interventions | Sponsor/Collaborators | Phases | Start Date | Last Updated |
NCT00257010 | Migraine | Drug: Almotriptan Malate | Janssen-Ortho LLC|Ortho-McNeil Neurologics, Inc. | Phase 3 | 2005-12-01 | 2014-01-23 |
NCT00210483 | Migraine | Drug: almotriptan malate | Janssen-Ortho LLC|Ortho-McNeil Neurologics, Inc. | Phase 3 | 2003-07-01 | 2011-05-16 |
NCT00210496 | Migraine|Classic Migraine|Common Migraine | Drug: topiramate; almotriptan malate | Janssen-Ortho LLC|Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Phase 4 | 2005-06-01 | 2011-05-16 |
NCT00212823 | Migraine | Drug: almotriptan malate | Ortho-McNeil Neurologics, Inc. | Phase 4 | 2004-06-01 | 2011-05-17 |
NCT00210509 | Migraine | Drug: almotriptan malate | Janssen-Ortho LLC|Ortho-McNeil Neurologics, Inc. | Phase 4 | 2004-11-01 | 2011-05-16 |
NCT00725140 | Migraine | Almirall, S.A. | 2008-06-01 | 2015-05-29 | ||
NCT00432549 | Analgesic Rebound Headache | Drug: Almotriptan|Drug: Topiramate | The New England Center for Headache, P.C.|Ortho-McNeil Neurologics, Inc. | Phase 4 | 2007-01-01 | 2007-02-07 |
NCT00208065 | Migraine|Sinusitis | Drug: almotriptan or pseudoephedrine | Clinvest|Ortho-McNeil Neurologics, Inc. | Phase 4 | 2004-05-01 | 2009-05-05 |
NCT01435941 | Migraine Disorders | Drug: Non-steroidal anti-inflammatory drug (NSAID)|Drug: Triptan | GlaxoSmithKline | 2009-09-01 | 2011-09-21 | |
NCT01381497 | Migraine Disorders | Drug: Combination therapy of sumatriptan and naproxen sodium (SumaRT/Nap)|Drug: Triptan monotherapy | GlaxoSmithKline | 2010-03-01 | 2012-08-23 | |
NCT01381523 | Migraine Disorders | Drug: Combination therapy with sumatriptan and naproxen sodium (SumaRT/Nap)|Drug: Single-entity oral triptans | GlaxoSmithKline | 2010-11-01 | 2013-02-21 | |
NCT01332500 | Migraine Disorders | Drug: Sumatriptan/Naproxen combination|Drug: other oral triptans | GlaxoSmithKline | 2009-07-01 | 2011-04-19 | |
NCT01086358 | Workplace Migraine Treatment | Drug: Usual prescribed triptan|Drug: Treximet for migraine treatment | The Cleveland Clinic|Pernix Theraputics LLC | Phase 4 | 2009-09-01 | 2016-08-10 |
注:以上所有数据均来自公开文献,并不保证对所有实验均有效,数据仅供参考。
相关化合物库
使用AMQUAR产品发表文献后请联系我们